Repros' Hypogonadism Treatment Enclomiphene Heads To FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Efficacy and safety data for drug, formerly known as Androxal, will be vetted by FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee Nov. 3.
You may also be interested in...
FDA’s Tough Stance On Patient-Reported Outcomes Underscored At Repros Meeting
US FDA advisory committee's insistence on symptom benefit as an efficacy endpoint for obesity-related secondary hypogonadism highlights importance of Repros' current efforts to lay groundwork for a patient-reported outcomes instrument for further study of enclomiphene.
Repros Low-Testosterone Therapy NDA May Be Delayed Until 4Q 2014
The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.